BRIEF-Evelo Biosciences Announces EDP1815 To Advance Into Phase 2/3 Tactic-E COVID-19 Trial - Reuters

June 22 (Reuters) - Evelo Biosciences Inc:

* EVELO BIOSCIENCES ANNOUNCES EDP1815 TO ADVANCE INTO PHASE 2/3 TACTIC-E COVID-19 TRIAL

* INTERIM DATA EXPECTED IN Q4 OF 2020

* PHASE 2/3 PLATFORM TRIAL SPONSORED BY CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST

* EDP1815 HAS BEEN OBSERVED TO HAVE FAVORABLE TOLERABILITY AND ANTI-INFLAMMATORY ACTIVITY IN A PRIOR CLINICAL TRIAL Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

Let's block ads! (Why?)

"tactic" - Google News
June 22, 2020 at 01:04PM
https://ift.tt/2Nj8XDI

BRIEF-Evelo Biosciences Announces EDP1815 To Advance Into Phase 2/3 Tactic-E COVID-19 Trial - Reuters
"tactic" - Google News
https://ift.tt/2NLbO9d
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update

Bagikan Berita Ini